公开(公告)号：US20220370355A1

公开(公告)日：2022-11-24

申请号：US17812479

申请日：2022-07-14

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K9/14 ,  A61K31/5365 ,  A61K47/26

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

公开(公告)号：US20220096423A1

公开(公告)日：2022-03-31

申请号：US17492231

申请日：2021-10-01

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Michael BALTEZOR ,  Charles DECEDUE ,  Sam CAMPBELL ,  Matthew MCCLOREY

IPC: A61K31/337 ,  A61K47/26 ,  A61K9/16 ,  A61P35/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14

Abstract: Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles. Administration methods include intratumoral injection, direct injection into surgical tumor resection sites, and intravesical instillation.

公开(公告)号：US20220023215A1

公开(公告)日：2022-01-27

申请号：US17381786

申请日：2021-07-21

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K9/14 ,  A61K31/5365 ,  A61K47/26

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

公开(公告)号：US20210393569A1

公开(公告)日：2021-12-23

申请号：US17467655

申请日：2021-09-07

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS ,  Gary E. CLAPP

IPC: A61K31/337 ,  A61K9/00 ,  A61K9/10 ,  A61K9/14 ,  A61K9/16 ,  B01J19/10 ,  B01J19/26 ,  B01J2/04 ,  B01J3/00 ,  B01J4/00 ,  A61K9/51 ,  A61J3/02 ,  B01D46/24 ,  B01J3/02 ,  B05B1/34 ,  B05B13/02

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

公开(公告)号：US20210000786A1

公开(公告)日：2021-01-07

申请号：US17023635

申请日：2020-09-17

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS ,  Gary E. CLAPP

IPC: A61K31/337 ,  A61K9/00 ,  A61K9/10 ,  A61K9/14 ,  A61K9/16 ,  B01J19/10 ,  B01J19/26 ,  B01J2/04 ,  B01J3/00 ,  B01J4/00 ,  A61K9/51 ,  A61J3/02 ,  B01D46/24 ,  B01J3/02 ,  B05B1/34 ,  B05B13/02

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

公开(公告)号：US20200261367A1

公开(公告)日：2020-08-20

申请号：US16834155

申请日：2020-03-30

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Michael BALTEZOR ,  Sam CAMPBELL ,  Charles J. DECEDUE ,  Matthew MCCLOREY

IPC: A61K9/16 ,  A61K31/337 ,  C07K16/28

Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

公开(公告)号：US20160354336A1

公开(公告)日：2016-12-08

申请号：US15174505

申请日：2016-06-06

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS

IPC: A61K31/337 ,  A61K9/16

CPC classification number: A61K31/337 ,  A61J3/02 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/14 ,  A61K9/1605 ,  A61K9/1682 ,  A61K9/1688 ,  A61K9/5192 ,  B01D46/24 ,  B01D2271/02 ,  B01J2/04 ,  B01J3/008 ,  B01J3/02 ,  B01J4/002 ,  B01J19/10 ,  B01J19/26 ,  B05B1/3489 ,  B05B13/0278 ,  B05D2401/90

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract translation: 提供的组合物包括具有至少95重量％的紫杉烷或其药学上可接受的盐，其中颗粒的平均堆积密度为约0.050g / cm 3至约0.15g / cm 3，和/或比表面积 面积（SSA）至少为18m2 / g，20m2 / g，25m2 / g，30m2 / g，32m2 / g，34m2 / g或35m2 / g。 还提供了制备和使用这些组合物的方法。